Pfizer/Eyetech Macugen Filing Planned For Q3 In All Three AMD Subgroups
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eyetech plans to submit its VEGF inhibitor Macugen in the third quarter for use in the three subtypes of wet age-related macular degeneration, the company noted in a prospectus for an initial public offering.